Skip to content

Study · Animal study (in vivo) · mouse · 2022

9 results

Nangibotide attenuates osteoarthritis by inhibiting osteoblast apoptosis and TGF-β activity in subchondral bone.

Zhong Y, Xu Y, Xue S, Zhu L, Lu H, Wang C, Chen H, Sang W, Ma J

Inflammopharmacology7 Apr 2022Cited by 12 (Europe PMC)

PMID35391646 (opens in a new tab)DOI10.1007/s10787-022-00984-2 (opens in a new tab)PepBankPUB-35391646
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In mice, nangibotide suppressed ACLT-induced cartilage degradation.

    In plain wordsIn mice, nangibotide reduced cartilage damage induced by ACLT.

    Peptide
    Nangibotide
    Outcome
    DecreaseCartilage degradation
    Study

    mousen: not reported in source

    ACLT-induced osteoarthritis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Nangibotide suppressed ACLT-induced cartilage degradation and MMP-13 expression.
    1 context sentence
    Summary · context
    Male C57BL/6 J mice aged 2 months were randomly allocated to three groups: sham, ACLT, and ACLT with nangibotide therapy.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In mice, nangibotide suppressed ACLT-induced MMP-13 expression.

    In plain wordsIn mice, nangibotide reduced MMP-13 expression induced by ACLT.

    Peptide
    Nangibotide
    Outcome
    DecreaseMMP-13 expression
    Study

    mousen: not reported in source

    ACLT-induced osteoarthritis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Nangibotide suppressed ACLT-induced cartilage degradation and MMP-13 expression.
    1 context sentence
    Summary · context
    Male C57BL/6 J mice aged 2 months were randomly allocated to three groups: sham, ACLT, and ACLT with nangibotide therapy.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In mice, nangibotide attenuated ACLT-induced subchondral bone loss.

    In plain wordsIn mice, nangibotide reduced bone loss beneath cartilage after ACLT.

    Peptide
    Nangibotide
    Outcome
    DecreaseSubchondral bone loss
    Study

    mousen: not reported in source

    ACLT-induced osteoarthritis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MicroCT analysis revealed that nangibotide attenuated in vivo subchondral bone loss induced by ACLT.
    1 context sentence
    Summary · context
    Male C57BL/6 J mice aged 2 months were randomly allocated to three groups: sham, ACLT, and ACLT with nangibotide therapy.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice, nangibotide attenuated ACLT-induced osteoblast inhibition.

    In plain wordsIn mice, nangibotide reduced inhibition of bone-forming cells after ACLT.

    Peptide
    Nangibotide
    Outcome
    DecreaseOsteoblast inhibition
    Study

    mousen: not reported in source

    ACLT-induced osteoarthritis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Histomorphometry results showed that nangibotide attenuated ACLT-induced osteoblast inhibition; TUNEL assays and immunohistochemical staining of cleaved-caspase3 further confirmed the in vivo anti-apoptotic effect of nangibotide on osteoblasts.
    1 context sentence
    Summary · context
    Male C57BL/6 J mice aged 2 months were randomly allocated to three groups: sham, ACLT, and ACLT with nangibotide therapy.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In mice with ACLT-induced osteoarthritis, nangibotide had an anti-apoptotic effect on osteoblasts.

    In plain wordsIn mice, nangibotide reduced programmed death of bone-forming cells after ACLT.

    Peptide
    Nangibotide
    Outcome
    DecreaseOsteoblast apoptosis in vivo
    Study

    mousen: not reported in source

    ACLT-induced osteoarthritis
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Histomorphometry results showed that nangibotide attenuated ACLT-induced osteoblast inhibition; TUNEL assays and immunohistochemical staining of cleaved-caspase3 further confirmed the in vivo anti-apoptotic effect of nangibotide on osteoblasts.
    1 context sentence
    Summary · context
    Male C57BL/6 J mice aged 2 months were randomly allocated to three groups: sham, ACLT, and ACLT with nangibotide therapy.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In the osteoarthritis model, nangibotide suppressed Smad2/3-mediated TGF-β signaling to restore coupled subchondral bone remodeling.

    In plain wordsIn mice, nangibotide suppressed TGF-β signaling to restore coordinated bone remodeling beneath cartilage.

    Peptide
    Nangibotide
    Outcome
    DecreaseSmad2/3-mediated TGF-β signaling
    Study

    mousen: not reported in source

    ACLT-induced osteoarthritis
    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, we found that nangibotide exerted protective effects by suppressing TGF-β signaling mediated by Smad2/3 to restore coupled bone remodeling in the subchondral bone.
    1 context sentence
    Summary · context
    Male C57BL/6 J mice aged 2 months were randomly allocated to three groups: sham, ACLT, and ACLT with nangibotide therapy.
  7. 07LabIn vitro (cells)Efficacy outcome

    In MC3T3-E1 cells, nangibotide inhibited TNF-α-induced osteogenic reduction.

    In plain wordsIn cells, nangibotide reduced the loss of bone-forming activity induced by TNF-α.

    Peptide
    Nangibotide
    Outcome
    DecreaseTNF-α-induced osteogenic reduction
    Study

    n: not reported in source

    MC3T3-E1 cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro experiments showed that nangibotide strongly inhibited TNF-α-induced osteogenic reduction, significantly enhanced osteoblast proliferation and prevented apoptosis in MC3T3-E1 cells.
  8. 08LabIn vitro (cells)Efficacy outcome

    In MC3T3-E1 cells, nangibotide significantly enhanced osteoblast proliferation.

    In plain wordsIn cells, nangibotide increased bone-forming cell proliferation.

    Peptide
    Nangibotide
    Outcome
    IncreaseOsteoblast proliferation
    Study

    n: not reported in source

    MC3T3-E1 cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro experiments showed that nangibotide strongly inhibited TNF-α-induced osteogenic reduction, significantly enhanced osteoblast proliferation and prevented apoptosis in MC3T3-E1 cells.
  9. 09LabIn vitro (cells)Mechanism

    In MC3T3-E1 cells, nangibotide prevented apoptosis.

    In plain wordsIn cells, nangibotide prevented programmed death of bone-forming cells.

    Peptide
    Nangibotide
    Outcome
    DecreaseOsteoblast apoptosis
    Study

    n: not reported in source

    MC3T3-E1 cells
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vitro experiments showed that nangibotide strongly inhibited TNF-α-induced osteogenic reduction, significantly enhanced osteoblast proliferation and prevented apoptosis in MC3T3-E1 cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:32 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.